Skip to main content

Table 6 Cox regression analysis assessing the potential of clinical and epigenetic variables in the prediction of disease-specific survival and disease-free survival in the Cohort #1 and Cohort #2

From: MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors

Cohort #1
Disease-specific survival – Cox regression analysis Disease-free survival – Cox regression analysis
Variable HR CI (95%) P Variable HR CI (95%) P
Gleason Score Gleason Score
<7 1   
≤7 1    7 3.96 1.76–8.91 0.001
>7 18.97 4.32–83.351 <0.001 >7 7.73 2.85–21.0 <0.001
miR–129-2 PSA
≤ P75 1    <10 1   
> P75 6.12 1.56–24.07 0.009 ≥10 1.87 1.07–3.26 0.027
Cohort #2
Disease-specific survival – Cox regression analysis Disease-free survival – Cox regression analysis
Variable HR CI (95%) P Variable HR CI (95%) P
Clinical stage     Clinical stage    
II 1    II 1   
III/IV 9.64 2.60-35.8 <0.001 III/IV 2.57 1.18-5.60 0.018
miR-34b/c miR-34b/c
≤ P75 1    ≤ P75 1   
> P75 3.84 1.27–11.6 0.017 > P75 2.76 1.24–6.15 0.013
  1. HR hazard ratio, CI confidence interval